Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 13, 2002. The report details a specific corporate action regarding share re-purchases executed on October 30, 2002, pursuant to shareholder authority granted at the Annual General Meeting on May 20, 2002.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share re-purchase transaction:
- Shares Purchased: 820,000 Ordinary 25 pence shares.
- Price per Share: 1,213.53 pence.
- Transaction Date: October 30, 2002.
- Use of Proceeds: Purchased for cancellation.
Material Changes
The filing does not disclose material changes in revenue, operating results, or financial position compared to prior periods. The primary change reported is the reduction in the number of outstanding shares due to the cancellation of 820,000 shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, risk factors, or contingencies. It is a notification of a completed capital transaction.
Key Facts for Investor Verification
- Verify the total number of shares outstanding post-cancellation to assess the impact on earnings per share.
- Confirm the total cash outflow for the re-purchase (820,000 shares x 1,213.53 pence) against the company's cash reserves.
- Check subsequent filings to determine if the remaining authority granted at the May 2002 AGM was utilized for further re-purchases.